Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: Anthony Wong who wrote (2638)	5/21/1998 12:01:00 AM
From: Jim Lamb	Read Replies (1) \| Respond to of 9523

From Forbes Some of the Viagra winners By Vicki Contavespi f the total 9,091 funds that Morningstar monitors, 993 own a piece of Pfizer. Pfizer has been on a tear recently thanks to its recent Viagra drug, already labeled Pfizer riser among the trading community. In the past three years, Pfizer has grown 402%, easily outpacing the S&P 500's 126%. This year alone the New York City-based drug company has risen 52%, compared with almost 18% for the S&P. The $21 billion Janus (JANSX) and the 4.5 billion Janus Twenty (JAVLX) funds own 10.8 million shares in Pfizer, accounting for just under 1% of Pfizer's total shares outstanding. This has been a boon for Janus Twenty, since Pfizer is its third-largest holding. Another big Pfizer owner, in terms of percentage of net assets, is the $1.1 billion Invesco Strategic Health Science (FHLSX) fund, with a 7.47% stake and a year-to-date return of 16.92%. Its top four holdings--Pfizer, Merck, Bristol-Myers Squibb and SmithKline Beecham--are all strong performers. New England Growth A (NEFGX), with $1.6 billion in net assets, has 6.43%, or 1.3 million shares, tied up in Pfizer. It's probably happy it does, recording a year-to-date return of 17.68%. White Oak Growth Stock (WOGSX) is another happy customer. With only $563 million in net assets, its 5.4% allotment of Pfizer contributed mightily to its 17.31% return so far this year. The Davis Growth Opportunity A (RPEAX), with net assets of $61.5 million, and Davis Growth Opportunity B (RPFEX), with net assets of $48.2 million, have 7.65% of their assets--some 112,000 of Pfizer's shares--between them. Even so, their returns, at just over 13.5%, aren't showing the drug's effects, probably because each fund also holds significant stakes in Cendent, which had its dramatic collapse a couple of weeks ago, losing almost 50% of its market value in one day.